Jost Fischer bought $55k of AEON
director at AEON Biopharma, Inc.. 110,000 shares at an average of $0.50, traded May 19, 2025, filed May 21, 2025.
Score components
- +15RoleDirector
- +7Trade size$55k at market
- +10Relative to holdingsHoldings up 114%
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +53.1%, 3m +42.8%, 6m +93.4%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001610717-25-000124, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 19, 2025 | POpen-market purchase Class A Common Stock | +50,000 | $0.50 | $25k | 146,785 | May 21, 2025 |
| May 20, 2025 | POpen-market purchase Class A Common Stock | +60,000 | $0.51 | $30k | 206,785 | May 21, 2025 |
Related signals
Other insiders at AEON Biopharma, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 44Moderate | AEONbuy AEON Biopharma, Inc. | Timothy P Lynch owner | $243k 1,150,000 shares | +21% | |
| 31Weak | AEONbuy AEON Biopharma, Inc. | Jost Fischer director | $29k 60,000 shares | +29% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.